Free online tool helps prostate cancer patients save on out-of-pocket drug costs

A study shows that comparing Medicare Part D prescription plans can lead to significant savings in cost of cancer care

11:15 AM

Author | Nicole Fawcett

man at table writing down in living room
Getty Images

A free online tool could potentially save some prostate cancer patients more than $9,000 in out-of-pocket drug costs, a study finds.

For patients enrolled in Medicare Part D prescription drug plans, out of pocket costs can vary significantly.

But by using an online Medicare plan finder tool, patients can compare pricing among all Part D drug plans offered in their area and select the most affordable plan.

Researchers from the University of Michigan Health Rogel Cancer Center found that the Medicare Part D Plan Finder, which is funded by the Centers for Medicare and Medicaid Services, can identify significant savings for patients taking abiraterone or enzalutamide, two common prescription drugs for advanced prostate cancer.

“Patients with Medicare Part D have dozens of different drug plans available to choose from, but most patients unfortunately are not aware of this. If they compare estimated costs, they could save thousands of dollars each year in drug costs. This could make a huge impact for patients with limited resources,” said lead study author Benjamin Pockros, M.D., M.B.A., a urology resident at Michigan Medicine.

The researchers looked at out-of-pocket costs for abiraterone and enzalutamide, using the Medicare Part D Plan Finder to compare within 12 different regions across the country that have prominent prostate cancer programs.

Out-of-pocket costs for abiraterone prescriptions ranged from $1,379 to $13,274 among all Part D plans.

The median potential cost savings among all 12 cities was $9,321. For enzalutamide, out-of-pocket cost ranged from $9,854 to $13,061.

The median potential cost savings among all 12 cities was $1,839. The study is published in Urology Practice.

“We know cancer can take a devastating physical, emotional and financial toll on patients. For those enrolled in Medicare Part D, this plan finder is free and easy to use, and hopefully one small step in improving cancer care in our country,” Pockros said.

The plan finder is available online at medicare.gov/plan-compare.

Patients enter their zip code and prescription drugs; the finder displays estimated annual out-of-pocket costs for local retail and mail order pharmacies.

Medicare offers an annual open enrollment period from Oct. 15-Dec. 7, during which people can switch plans.

More than 49 million Americans are enrolled in Medicare Part D, and some patients have up to 50 different plans to choose from. Despite significant cost differences, fewer than 30% of patients report comparing drug plan pricing.

The study authors urge providers to speak to patients about using the plan finder.

They are now leading a project funded by the Rogel Cancer Center and U-M Institute for Healthcare Policy and Innovation to help make cancer patients more aware of the Medicare Part D Plan Finder to help minimize out-of-pocket drug costs.

Additional authors: Christina Shabet; Kristian Stensland, M.D., M.P.H., M.S.; Lindsey Herrel, M.D., M.S.

Paper cited: “Out-of-Pocket Costs for Prostate Cancer Medications Substantially Vary by Part D Plan: An Online Tool Presents an Opportunity to Mitigate Financial Toxicity,” Urology Practice. DOI: 10.1097/UPJ.0000000000000421


More Articles About: Cancer (Oncology) Prostate Cancer Prostate Conditions Cancer Treatment Hormonal Therapy for Cancer Health Care Delivery, Policy and Economics Hospitals & Centers Community Health
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories three friends standing outside rogel cancer center building with big white ribbons
Health Lab
A lung cancer survivor shaping lung cancer advocacy
One woman's unexpected lung cancer diagnosis leads her to help many who aren't aware they're at risk of the disease.
frozen dial with ice on it with red dial
Health Lab
Enzyme identified as new therapeutic target for “cold” tumors
A study identifies an enzyme as a new therapeutic target for “cold” tumors.
On left, a young boy in a wheelchair has his doctor standing to his left and his parent is standing to his right in a show of support. On the right side of the image, the boy is now an adult and is wondering about the cost of his care and if his questions will be answered.
Health Lab
Changing the definition of cerebral palsy
Cerebral palsy is defined as a childhood disorder, which fails to recognize adults living with the condition and the lack of care they receive once they age out of pediatric clinics.
purple gloves close up holding piece
Health Lab
Recycled pacemakers function as well as new devices, international study suggests
Recycled pacemakers can function as well as new devices, a University of Michigan-led study suggests. These used and reconditioned devices have the potential to increase access to pacemaker therapy in low- and middle-income countries, where many patients cannot afford the treatment.
pigs sick and chickens in background with blue background and green cells floating around
Health Lab
Why the bird flu’s jump to pigs is concerning
A Michigan Medicine virologist speaks about the implications of H5N1 influenza, or bird flu, and whether a new pandemic could be on the horizon.
floating AI-type images in red and blues and yellow on blue background
Health Lab
Racial differences in medical testing could introduce bias to AI models
Black patients are less likely than white patients to receive certain medical tests that doctors use to diagnose severe disease, impacting artificial intelligence data. But researchers have found a way to correct the bias in these data sets.